<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="C_8876857e-5294-43b8-9511-7c1830c7fadc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671584</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-24</startDate>
            <endDate>2026-07-24</endDate>
        </period>
    </context>
    <context id="C_3c62eec6-8c8d-4ff5-8f72-b3c6a707950e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671584</identifier>
        </entity>
        <period>
            <startDate>2026-07-24</startDate>
            <endDate>2026-07-24</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <ffd:OffsetTableNa
      contextRef="C_3c62eec6-8c8d-4ff5-8f72-b3c6a707950e"
      id="F_fa319ce5-79e5-45d0-bcd1-d1082f3589bf">N/A</ffd:OffsetTableNa>
    <dei:EntityCentralIndexKey
      contextRef="C_3c62eec6-8c8d-4ff5-8f72-b3c6a707950e"
      id="F_13d6f9c9-2cf4-4f2b-886b-594e1cf9cce6">0001671584</dei:EntityCentralIndexKey>
    <ffd:FeeExhibitTp
      contextRef="C_3c62eec6-8c8d-4ff5-8f72-b3c6a707950e"
      id="F_b23dc2f1-9231-49a2-9e9b-c58adce90c36">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:FormTp
      contextRef="C_3c62eec6-8c8d-4ff5-8f72-b3c6a707950e"
      id="F_95d83b8b-6fb8-44ff-b76f-2765bbfaef1d">S-8</ffd:FormTp>
    <ffd:SubmissnTp
      contextRef="C_3c62eec6-8c8d-4ff5-8f72-b3c6a707950e"
      id="F_38279f12-06c7-40e9-afdd-5e6491aecce9">S-8</ffd:SubmissnTp>
    <dei:EntityRegistrantName
      contextRef="C_3c62eec6-8c8d-4ff5-8f72-b3c6a707950e"
      id="F_58ac4eb7-69ae-49fe-991f-c042636ff3b0">Aptevo Therapeutics Inc.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg
      contextRef="C_8876857e-5294-43b8-9511-7c1830c7fadc"
      id="F_1a2f373f-06a3-411d-b5b8-88129d83d126">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp
      contextRef="C_8876857e-5294-43b8-9511-7c1830c7fadc"
      id="F_1f8cd514-3931-4ea2-8af0-1f1c576754e5">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl
      contextRef="C_8876857e-5294-43b8-9511-7c1830c7fadc"
      id="F_f7d87384-0b59-4aae-8ab1-119ac3dca3c9">Common Stock, $0.001 par value per share, reserved for issuance under the Third Amended and Restated 2018 Stock Incentive Plan</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg
      contextRef="C_8876857e-5294-43b8-9511-7c1830c7fadc"
      id="F_718c6456-7eb3-4d65-a2d1-56b8aff6229f">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="C_8876857e-5294-43b8-9511-7c1830c7fadc"
      decimals="0"
      id="F_5db952a0-85d7-4242-a187-3f071622bfba"
      unitRef="U_USD">13888</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="C_8876857e-5294-43b8-9511-7c1830c7fadc"
      decimals="2"
      id="F_b557086d-5a3a-4a7d-838f-07ba976fd8b4"
      unitRef="U_USD">4.44</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="C_8876857e-5294-43b8-9511-7c1830c7fadc"
      decimals="2"
      id="F_308e8a20-530d-44a0-8a41-b9fbbbc55f49"
      unitRef="U_USD">61663</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="C_8876857e-5294-43b8-9511-7c1830c7fadc"
      decimals="7"
      id="F_fe8724a2-62ee-4aec-80c7-9b705a53c5a6"
      unitRef="U_pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="C_8876857e-5294-43b8-9511-7c1830c7fadc"
      decimals="2"
      id="F_8e90ca8a-2734-4bba-8f8b-844dc80592b4"
      unitRef="U_USD">9</ffd:FeeAmt>
    <ffd:TtlOfferingAmt
      contextRef="C_3c62eec6-8c8d-4ff5-8f72-b3c6a707950e"
      decimals="2"
      id="F_5f078f5d-812e-4638-af35-c2a15cbae9d1"
      unitRef="U_USD">61663</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt
      contextRef="C_3c62eec6-8c8d-4ff5-8f72-b3c6a707950e"
      decimals="2"
      id="F_6c6f3d0a-4202-4dbd-bf49-be6c67ef633d"
      unitRef="U_USD">9</ffd:TtlFeeAmt>
    <ffd:TtlOffsetAmt
      contextRef="C_3c62eec6-8c8d-4ff5-8f72-b3c6a707950e"
      decimals="2"
      id="F_0e93ab7e-50e6-4d16-8958-277e30b5b92b"
      unitRef="U_USD">0</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt
      contextRef="C_3c62eec6-8c8d-4ff5-8f72-b3c6a707950e"
      decimals="2"
      id="F_8e86e08c-69b9-4dcb-9069-1b23d78ad985"
      unitRef="U_USD">9</ffd:NetFeeAmt>
    <ffd:OfferingNote
      contextRef="C_8876857e-5294-43b8-9511-7c1830c7fadc"
      id="F_74b0d72b-32ed-4277-971a-11f21206516e">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;a. In accordance with Rule 416(a) under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), this registration statement on Form S-8 (the &#x201c;Registration Statement&#x201d;) shall be deemed to cover any additional shares of Common Stock, $0.001 par value per share (the &#x201c;Common Stock&#x201d;) of Aptevo Therapeutics Inc. (the &#x201c;Company&#x201d;) that become issuable under the Third Amended and Restated 2018 Stock Incentive Plan by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Common Stock, as applicable.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;b. Represents 13,888 shares of Common Stock reserved for issuance under the Third Amended and Restated 2018 Stock Incentive Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;c. Estimated in accordance with Rules 457(c) and 457(h) of the Securities Act based upon the average of the high and low sale prices of the Common Stock as reported on the Nasdaq Stock Market on July 22, 2026.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;d. The Registrant does not have any fee offsets.&lt;/span&gt;&lt;/p&gt;</ffd:OfferingNote>
</xbrl>
